GC
AKBA icon

Guggenheim Capital’s Akebia Therapeutics AKBA Stock Holding History

Guggenheim Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,039
Closed -$1.9K – 1860
2024
Q1 		$1.9K Buy
+1,039
New +$1.66K ﹤0.01% 1868
2017
Q3 		– Sell
-10,921
Closed -$157K – 2801
2017
Q2 		$157K Sell
10,921
-341
-3% -$4.32K ﹤0.01% 2663
2017
Q1 		$103K Buy
+11,262
New +$110K ﹤0.01% 2692

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Guggenheim Capital's AKBA Position: Q2 2024 in Review

Guggenheim Capital sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 1,039 shares — an estimated $1.9K sold.

Guggenheim Capital first reported a position in AKBA in Q1 2017 and held it in 3 quarters. The position peaked at $157K in Q2 2017. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

  • Guggenheim Capital reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Guggenheim Capital sold 1,039 Akebia Therapeutics shares in Q2 2024, an estimated $1.9K.
  • Guggenheim Capital first reported a position in Akebia Therapeutics in Q1 2017 and held it in 3 quarters.
  • Guggenheim Capital's Akebia Therapeutics position peaked at $157K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Guggenheim Capital's 13F filing for Q2 2024, filed 14 Aug 2024.